SPY317.21+0.16 0.05%
DIA261.53-1.47 -0.56%
IXIC10,507.07+73.42 0.70%

Principia Announces First Patient Enrolled in Sanofi's Phase 3 Trial of SAR442168 in Relapsing MS

Principia Biopharma Inc. (NASDAQ: PRNB) today announced that the first patient has been enrolled in its partner Sanofi's Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS). Upon dosing, Principia will be entitled to a $

Benzinga · -
Principia Biopharma Inc. (NASDAQ: PRNB) today announced that the first patient has been enrolled in its partner Sanofi's Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS). Upon dosing, Principia will be entitled to a $50 million milestone payment. SAR442168, discovered by Principia and formerly known as PRN2246, is a Bruton's tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the central nervous system (CNS), which shows promise for the potential treatment of CNS diseases. "We are delighted that Sanofi has initiated a Phase 3 trial in patients with relapsing MS," said Roy Hardiman, chief business officer at Principia. "Our partnership with Sanofi (NYSE: SNY), a company with a long track record of bringing novel therapies to the multiple sclerosis community, is highly collaborative. We continue to evaluate our Phase 3 co-funding option that could increase Principia's economic rights."